Home > Products > Featured products

Pam3CSK4 TFA

  Cat. No.:  DC29108   Featured
Chemical Structure
112208-01-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 112208-01-2
Chemical Name: Pam3CSK4 TFA
Synonyms: Pam3Cys-Ser-(Lys)4 TFAPam3Cys-Ser-(Lys)4 TFA;Pam3CSK4 TFA;Pam3CSK4 trifluoroacetate;Pam3CSK4 trifluoroacetate;Pam3Cys-Ser-(Lys)4 TFA;Pam3Cys-Ser-(Lys)4 TFA;112208-01-2;112208-01-2;(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-3-{[2,3-bis(hexadecanoyloxy)propyl]sulfanyl}-2-hexadecanamidopropanamido]-3-hydroxypropanamido]hexanamido]hexanamido]hexanamido]hexanoic acid; tris(trifluoroacetic acid);(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-3-{[2,3-bis(hexadecanoyloxy)propyl]sulfanyl}-2-hexadecanamidopropanamido]-3-hydroxypropanamido]hexanamido]hexanamido]hexanamido]hexanoic acid; tris(trifluoroacetic acid);AKOS040763884;AKOS040763884;TS-10283;TS-10283
SMILES: S(CC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C[C@@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)=O)NC(CCCCCCCCCCCCCCC)=O.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F
Formula: C87H159F9N10O19S
M.Wt: 1852.29961705208
Purity: 98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
TITLE DOWNLOAD
MSDS_13158_DC29108_112208-01-2
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC48724 AXC-715 trihydrochloride AXC-715 trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.
DC44159 Enpatoran Enpatoran (M5049) is an orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran can block both innate and adaptive autoimmunity. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran (M5049) can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran (M5049) inhibits cytokine release, causing great potency in pharmacokinetic/pharmacodynamic properties.
DC42507 CU-115 CU115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM). CU 115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells.
DC29108 Pam3CSK4 TFA Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2.
DC28692 TLR7/8 agonist 3 TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent US20170114137A1.
DC28351 1V209(TLR7 agonist T7) 1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
DC28230 Loxoribine Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist.
DC7305 TAK-242 (Resatorvid) TAK-242 (Resatorvid), a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia